← Leaderboards
Daniel Paris
Archer Pharmaceuticals, Inc.
$653,772
Attributed
$1,886,317
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $812.4K · FY2011–21$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,886,317 · 2
By mechanism
R42$1,736,317 · 1
R43$150,000 · 1
Top collaborators
- Bruce E Blough3 shared
- Michael Mullan3 shared
- Fiona C. Crawford1 shared
Most similar at Archer Pharmaceuticals, Inc.
Same institution · by research overlap
- Michael Mullan$578,772
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBaseDementiaPharmaceutical PreparationsToxic EffectPre-Clinical ModelIn VivoImpaired CognitionMetabolismPeptidesS DiseasePre-ClinicalAmyloidToxicologyBrainClinical TrialsAffectAntihypertensive AgentsChronicLeadMouse ModelAmyloid Beta-ProteinAbnormally Phosphorylated TauAllosteric Site
Grant awards (4)
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$699,018
R42 · FY2021 · AG
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$812,379
R42 · FY2020 · AG
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$224,920
R42 · FY2018 · AG
Pre-clinical Development of a Therapeutic for Alzheimer's Disease$150,000
R43 · FY2011 · AG · contact PI